123 related articles for article (PubMed ID: 32429649)
21. Fibroepithelial lesions; The WHO spectrum.
Krings G; Bean GR; Chen YY
Semin Diagn Pathol; 2017 Sep; 34(5):438-452. PubMed ID: 28688536
[TBL] [Abstract][Full Text] [Related]
22. Early-onset malignant phyllodes breast tumor in a patient with germline pathogenic variants in NF1 and BRCA1 genes.
Gensini F; Sestini R; De Luca A; Pinna V; Daniele P; Orzalesi L; Petrella MC; Porfirio B; Papi L
Fam Cancer; 2021 Jul; 20(3):195-199. PubMed ID: 33210232
[TBL] [Abstract][Full Text] [Related]
23. Genomic landscapes of breast fibroepithelial tumors.
Tan J; Ong CK; Lim WK; Ng CC; Thike AA; Ng LM; Rajasegaran V; Myint SS; Nagarajan S; Thangaraju S; Dey S; Nasir ND; Wijaya GC; Lim JQ; Huang D; Li Z; Wong BH; Chan JY; McPherson JR; Cutcutache I; Poore G; Tay ST; Tan WJ; Putti TC; Ahmad BS; Iau P; Chan CW; Tang AP; Yong WS; Madhukumar P; Ho GH; Tan VK; Wong CY; Hartman M; Ong KW; Tan BK; Rozen SG; Tan P; Tan PH; Teh BT
Nat Genet; 2015 Nov; 47(11):1341-5. PubMed ID: 26437033
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors in breast phyllodes tumors: a nomogram based on a retrospective cohort study of 404 patients.
Zhou ZR; Wang CC; Sun XJ; Yang ZZ; Chen XX; Shao ZM; Yu XL; Guo XM
Cancer Med; 2018 Apr; 7(4):1030-1042. PubMed ID: 29479819
[TBL] [Abstract][Full Text] [Related]
25. Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors.
Barth RJ
Breast Cancer Res Treat; 1999 Oct; 57(3):291-5. PubMed ID: 10617306
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical characteristics between benign borderline and malignant phyllodes tumors of the breast.
Wang H; Wang X; Wang CF
Asian Pac J Cancer Prev; 2014; 15(24):10791-5. PubMed ID: 25605178
[TBL] [Abstract][Full Text] [Related]
27. MicroRNAs are differentially deregulated in mammary malignant phyllodes tumour.
Tsang JY; Ni YB; Ng EK; Shin VY; Mak KF; Go EM; Tawasil J; Chan SK; Ko CW; Kwong A; Tse GM
Histopathology; 2015 Sep; 67(3):294-305. PubMed ID: 25585495
[TBL] [Abstract][Full Text] [Related]
28. Chromosomal aberrations and genetic relations in benign, borderline and malignant phyllodes tumors of the breast: a comparative genomic hybridization study.
Lv S; Niu Y; Wei L; Liu Q; Wang X; Chen Y
Breast Cancer Res Treat; 2008 Dec; 112(3):411-8. PubMed ID: 18189161
[TBL] [Abstract][Full Text] [Related]
29. Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast--implications for tumor biology and pathological diagnosis.
Pfarr N; Kriegsmann M; Sinn P; Klauschen F; Endris V; Herpel E; Muckenhuber A; Jesinghaus M; Klosterhalfen B; Penzel R; Lennerz JK; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2015 Jul; 54(7):444-52. PubMed ID: 25931199
[TBL] [Abstract][Full Text] [Related]
30. Expression of EMT inducers integrin-linked kinase (ILK) and ZEB1 in phyllodes breast tumors is associated with aggressive phenotype.
Akrida I; Nikou S; Gyftopoulos K; Argentou M; Kounelis S; Zolota V; Bravou V; Papadaki H
Histol Histopathol; 2018 Sep; 33(9):937-949. PubMed ID: 29608014
[TBL] [Abstract][Full Text] [Related]
31. B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration.
Kim GE; Kim NI; Park MH; Lee JS
Tumour Biol; 2018 Nov; 40(11):1010428318815032. PubMed ID: 30486739
[TBL] [Abstract][Full Text] [Related]
32. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.
Yonemori K; Hasegawa T; Shimizu C; Shibata T; Matsumoto K; Kouno T; Ando M; Katsumata N; Fujiwara Y
Pathol Res Pract; 2006; 202(10):705-12. PubMed ID: 16889904
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities.
Jardim DL; Conley A; Subbiah V
Orphanet J Rare Dis; 2013 Jul; 8():112. PubMed ID: 23895135
[TBL] [Abstract][Full Text] [Related]
34. Risk of Local Recurrence of Benign and Borderline Phyllodes Tumors: A Danish Population-Based Retrospective Study.
Borhani-Khomani K; Talman ML; Kroman N; Tvedskov TF
Ann Surg Oncol; 2016 May; 23(5):1543-8. PubMed ID: 26714948
[TBL] [Abstract][Full Text] [Related]
35. [Clinicopathologic features and prognostic factors of malignant phyllodes tumors].
Jia C; Mei F; Zheng J; You JF; Liu JY
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):729-34. PubMed ID: 24447548
[TBL] [Abstract][Full Text] [Related]
36. Management of phyllodes breast tumors.
Guillot E; Couturaud B; Reyal F; Curnier A; Ravinet J; Laé M; Bollet M; Pierga JY; Salmon R; Fitoussi A;
Breast J; 2011; 17(2):129-37. PubMed ID: 21251125
[TBL] [Abstract][Full Text] [Related]
37. Genomic profile of breast sarcomas: a comparison with malignant phyllodes tumours.
Lim SZ; Ng CCY; Rajasegaran V; Guan P; Selvarajan S; Thike AA; Nasir NDBM; Koh VCY; Tan BKT; Ong KW; Teh BT; Tan PH
Breast Cancer Res Treat; 2019 Apr; 174(2):365-373. PubMed ID: 30511242
[TBL] [Abstract][Full Text] [Related]
38. Association of the BRCA1 missense variant R1699W with a malignant phyllodes tumor of the breast.
Rhiem K; Flucke U; Engel C; Wappenschmidt B; Reinecke-Lüthge A; Büttner R; Schmutzler RK
Cancer Genet Cytogenet; 2007 Jul; 176(1):76-9. PubMed ID: 17574969
[TBL] [Abstract][Full Text] [Related]
39. Frequent MED12 mutations in phyllodes tumours of the breast.
Yoshida M; Sekine S; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Ochiai A
Br J Cancer; 2015 May; 112(10):1703-8. PubMed ID: 25839987
[TBL] [Abstract][Full Text] [Related]
40. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
Kleer CG; Giordano TJ; Braun T; Oberman HA
Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
